NYSE: CAL

CALERES INC

CIK 0000014707 · Footwear

Large Revenue $2.8B Assets $2.0B as of Jul 16, 2026

Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.

Sign up free

Want to see a complete report first? Today's free report (THRM 10-Q) is open in full — no account needed.

10-Q Filed Jun 9, 2026 · Period ending May 2, 2026

Caleres Q1 revenue +8.5%, operating earnings double on Stuart Weitzman deal, tariff refunds

5 material changes detected. Sign up free to read the summary.

8-K Filed Jun 4, 2026 · Period ending Jun 4, 2026

Caleres reports Q1 2026 earnings for quarter ended May 2, 2026

2 material changes detected. Sign up free to read the summary.

Partner

Trade CAL commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

8-K Filed May 28, 2026 · Period ending May 28, 2026

Caleres shareholders approve 2026 equity plan and re-elect 10 directors at annual meeting

4 material changes detected. Sign up free to read the summary.

8-K Filed May 20, 2026 · Period ending May 20, 2026

Caleres promotes Daniel Karpel to permanent CFO with $550K salary, $1.3M equity package

3 material changes detected. Sign up free to read the summary.

10-K Filed Apr 2, 2026 · Period ending Jan 31, 2026

Caleres acquires Stuart Weitzman, swings to loss as margins compress despite sales growth

5 material changes detected. Sign up free to read the summary.

10-Q Filed Dec 11, 2025 · Period ending Nov 1, 2025

Summary not yet generated.

10-Q Filed Jun 10, 2025 · Period ending May 3, 2025

Summary not yet generated.

10-K Filed Apr 1, 2025 · Period ending Feb 1, 2025

Summary not yet generated.

Latest financial statements

From 10-Q filed Jun 9, 2026 (period ending May 2, 2026). SEC XBRL (companyfacts) — not generated by the model.

SEC XBRL

Consolidated Statements of Operations (Unaudited)

Description Q1 ended May 02, 2026 Q1 ended May 03, 2025
Revenue:
Total revenue / net sales 666.6 614.2
Cost of revenue / cost of sales 351.1 335.5
Gross profit 315.5 278.7
Operating expenses:
Selling, general and administrative 293.7 266.5
Other operating expenses, net (2.1) 0.6
Operating income 23.9 11.6
Other income/(expense), net 1.2 0.7
Income before income taxes 20.4 8.5
Income tax expense/(benefit) 6.6 2.5
Net income 14.3 6.9
Basic earnings per share 0.42 0.21
Diluted earnings per share 0.42 0.21

Consolidated Balance Sheets (Unaudited)

Description May 02, 2026 May 03, 2025
Current assets:
Cash and equivalents 37.7 33.1
Accounts receivable, net 173.9 160.4
Inventories 593.5 558.3
Prepaid expenses and other current assets 87.4 57.8
Assets held for sale 16.8
Other current assets 20.0 20.0
Total current assets 912.6 846.4
Property, plant and equipment, net 201.7 185.1
Operating lease right-of-use assets, net 571.8 559.7
Identifiable intangible assets, net 185.9 184.6
Goodwill 16.0 5.0
Deferred income taxes and other assets 5.6 5.2
Other long-term assets 128.5 121.8
TOTAL ASSETS 2,022 1,908
Current liabilities:
Line of credit 347.5 258.5
Current portion of operating lease liabilities 126.7 118.8
Accrued liabilities 204.5 171.7
Income taxes payable 14.0 8.7
Other current liabilities 190.5 212.5
Total current liabilities 883.2 770.3
Operating lease liabilities 475.1 473.0
Deferred income taxes and other liabilities 28.2 32.1
Shareholders' equity:
Common stock 0.3 0.3
Capital in excess of stated value 199.5 190.1
Accumulated other comprehensive income (loss) (17.8) (27.2)
Retained earnings (deficit) 430.0 441.9
Total shareholders' equity 612.1 605.2
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 2,022 1,908

Consolidated Statements of Cash Flows (Unaudited)

Description Q1 ended May 02, 2026 Q1 ended May 03, 2025
Operating Activities:
Net cash from operating activities (27.8) (5.7)
Investing Activities:
Net cash from investing activities (8.6) (21.1)
Financing Activities:
Net cash from financing activities 44.3 30.3
Net increase/(decrease) in cash 8.0 3.5

Amounts in millions USD; EPS as reported. Line labels are presentation-friendly mappings of filer XBRL tags — not a re-audit of the full statements. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗

View AI report for this filing